De-ventilation dyspnoea and sleep quality in COPD patients using NIV
Research type
Research Study
Full title
De-Ventilation dyspnoea and subjective sleep quality among patients with Chronic Obstructive Pulmonary Disease using home Non Invasive Ventilation
IRAS ID
305621
Contact name
dariusz wozniak
Contact email
Sponsor organisation
ROYAL PAPWORTH HOSPITAL
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
Home non-invasive ventilation (hNIV) is a widely used treatment for patients with chronic hypercapnic respiratory failure due to severe Chronic Obstructive Pulmonary Disease (COPD). In carefully selected patients it has been shown to improve nocturnal and daytime blood gas exchange, reduce readmission rates and prolong survival. High intensity NIV which employs high inspiratory positive airway pressure (IPAP) and a high respiratory back-up rate to maximise pCO2 reduction is currently the preferred method of ventilatory support for patients with COPD. However, it is not always well tolerated. Some patients experience severe breathlessness after being disconnected from the ventilator in the morning or when their NIV treatment is interrupted at night. This phenomenon, which has been described as de-ventilation dyspnoea, can potentially affect hNIV usage and quality of life but its prevalence and the underlying mechanisms are unknown. Some patients receiving hNIV report poor sleep quality but the magnitude of this problem and the associated factors have not been systematically examined in long-term hNIV users.
The main aims of this project are to determine the prevalence of de-ventilation dyspnoea and poor sleep quality in COPD patients receiving hNIV. We also wish to better understand what constitutes clinically significant de-ventilation dyspnoea by examining the relationship between its severity and important patient-oriented outcomes such us quality of life, sleep quality and adherence to hNIV. These data will allow us to examine whether any disease or treatment specific factors are associated with de-ventilation dyspnoea and poor sleep quality and help us to understand which patients are at risk of these complications. Through this study we will also identify patients who may benefit from novel methods of hNIV delivery.
We will invite all COPD patients established on hNIV in our centre. The study will take the form of a postal survey and retrospective data collection from patients’ records.REC name
London - Harrow Research Ethics Committee
REC reference
21/PR/1461
Date of REC Opinion
16 Nov 2021
REC opinion
Further Information Favourable Opinion